In the past few years, the united kingdom has witnessed a revolution in healthcare excess weight‑loss treatment options — from the introduction of semaglutide (Wegovy®) towards the increasing attractiveness of tirzepatide (Mounjaro®). Now, Yet another title is drawing notice in both of those medical and general public health and fitness circl